摘要
cART是目前国际上治疗艾滋病最有效的方法,但其仅能抑制病毒复制而无法清除病毒。“柏林患者”治愈成功后,艾滋病治愈成为艾滋病研究热点和治疗新目标。然而艾滋病治愈研究大多仍处于研究初步阶段,给人们带来了更多疾病治愈希望的同时,也出现了诸多的伦理问题,特别是cART中断(又称试验性停药,ATI)带来受试者风险和知情同意有效性的问题。本文通过分析艾滋病治愈研究中的技术和社会风险、受试者招募和知情同意、研究非直接参与者的风险以及治愈研究中的战争话语隐喻等几个焦点问题,进而提出艾滋病治愈研究的伦理治理建议,以期在伦理的规范和引导下,促进艾滋病治愈研究的健康发展。
Combination antiretroviral therapy(cART)is currently recognized internationally as the most effective treatment for HIV/AIDS.However,it only inhibits viral replication without eradicating the virus.The curative success in the case of the"Berlin Patient"has propelled HIV/AIDS cure into a research hotspot and a novel therapeutic objective.Nonetheless,the majority of HIV/AIDS cure research is still in its early,and while it has brought increased hope for disease eradication,and also raised a host of ethical concerns.These concerns are particularly pronounced in the context of cART interruption(also known as analytic treatment interruption,ATI),which raises questions about participant risk and the validity of informed consent.This article examines several key issues in HIV/AIDS cure research,including the technical and societal risks,participant recruitment and informed consent,the hazards to non-direct research participants,and the use of martial metaphors in cure research discourse.Subsequently,the article proposes recommendations for the ethical governance of HIV/AIDS cure research.The aim is to promote the sound conduct of such studies under the guidance and regulation of ethical standards,thereby contributing to the advancement of curative endeavors in the field of HIV/AIDS.
作者
邹琳
白晶
翟晓梅
马永慧
ZOU Lin;BAI Jing;ZHAI Xiaomei;MA Yonghui(Centre for Bioethics,School of Medicine,Xiamen University,Xiamen 361101,Fujian,China;National Institute for Nutrition and Health,Chinese Center for Disease Control and Prevention,Beijing 100050,China;School of Population Medicine and Public Health,Peking Union Medical College,Beijing 100732,China)
出处
《中国艾滋病性病》
CAS
CSCD
北大核心
2024年第5期531-536,共6页
Chinese Journal of Aids & STD
基金
福建生物科技伦理治理能力提升研究(FJ2022B146)
厦门大学校长基金项目,涉及人的生命科学和医学研究的免伦理审查制度研究(20720230067)。
